cevelestat sodium

Cevelestat sodium is a neutrophil elastase inhibitor under clinical investigation for the treatment of acute respiratory distress syndrome (ARDS) and systemic inflammatory response syndrome (SIRS), particularly in patients with severe acute brain injury. As a selective and competitive inhibitor of neutrophil elastase (a serine protease released by activated neutrophils), the drug works to mitigate the degradation of lung extracellular matrix and reduce vascular permeability, thereby improving oxygenation and pulmonary function. In clinical trial settings, such as those conducted at Changzhou Wujin People's Hospital, cevelestat sodium is administered via intravenous injection to evaluate its impact on 28-day all-cause mortality, inflammatory markers, and neurological recovery. The drug is identified in specific Chinese clinical registries and is closely related to or synonymous with sivelestat sodium, which is marketed in China under the brand name Saiwei.

Brand names

Saiwei

Other names

cevelestat sodiumsivelestat sodium赛维来司他钠